OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors
Kristopher W. Hoyt, Daniel A. Urul, Blessing C. Ogboo, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 1, pp. 2-16
Open Access | Times Cited: 15
Kristopher W. Hoyt, Daniel A. Urul, Blessing C. Ogboo, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 1, pp. 2-16
Open Access | Times Cited: 15
Showing 15 citing articles:
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
David E. Heppner, Blessing C. Ogboo, Daniel A. Urul, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14693-14696
Closed Access | Times Cited: 11
David E. Heppner, Blessing C. Ogboo, Daniel A. Urul, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14693-14696
Closed Access | Times Cited: 11
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6549-6569
Closed Access | Times Cited: 8
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6549-6569
Closed Access | Times Cited: 8
Lazertinib: Breaking the mold of third-generation EGFR inhibitors
Kishan B. Patel, David E. Heppner
RSC Medicinal Chemistry (2025)
Open Access | Times Cited: 1
Kishan B. Patel, David E. Heppner
RSC Medicinal Chemistry (2025)
Open Access | Times Cited: 1
Ascertaining a Structural Basis in Drug Discovery and Development
David E. Heppner
Journal of Medicinal Chemistry (2025)
Closed Access
David E. Heppner
Journal of Medicinal Chemistry (2025)
Closed Access
Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
Hui Tao, Bo Yang, Atena Farhangian, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Hui Tao, Bo Yang, Atena Farhangian, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells
Huan Ling, Lin Li, Liping Duan, et al.
Journal of the American Chemical Society (2025)
Closed Access
Huan Ling, Lin Li, Liping Duan, et al.
Journal of the American Chemical Society (2025)
Closed Access
EGFR Inhibitors Across Generations: Progress, Challenges, and Future Directions
Vishal G. Deshmukh, Suryakant B. Sapkal, Suchita S. Gadekar, et al.
Journal of Molecular Structure (2025), pp. 142326-142326
Closed Access
Vishal G. Deshmukh, Suryakant B. Sapkal, Suchita S. Gadekar, et al.
Journal of Molecular Structure (2025), pp. 142326-142326
Closed Access
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors
Son Pham, Boyang Zhao, Neetu Neetu, et al.
Journal of Virology (2025)
Open Access
Son Pham, Boyang Zhao, Neetu Neetu, et al.
Journal of Virology (2025)
Open Access
A Practical Guide for the Assay-Dependent Characterisation of Irreversible Inhibitors
Lavleen Mader, Jessica E. Borean, Jeffrey W. Keillor
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Lavleen Mader, Jessica E. Borean, Jeffrey W. Keillor
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Development of Highly Potent and Selective FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
(2024)
Open Access | Times Cited: 1
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
(2024)
Open Access | Times Cited: 1
Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 3, pp. 342-343
Open Access | Times Cited: 1
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 3, pp. 342-343
Open Access | Times Cited: 1
Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer
Adchata Konsue, Thomanai Lamtha, Duangkamol Gleeson, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 113, pp. 117906-117906
Closed Access | Times Cited: 1
Adchata Konsue, Thomanai Lamtha, Duangkamol Gleeson, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 113, pp. 117906-117906
Closed Access | Times Cited: 1
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors
Son Pham, Boyang Zhao, Neetu Neetu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Son Pham, Boyang Zhao, Neetu Neetu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Covalent Inhibitors of MAP Kinases
Surya K. De
Drug design and discovery (2024), pp. 159-189
Closed Access
Surya K. De
Drug design and discovery (2024), pp. 159-189
Closed Access
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors
Florian Wittlinger, Surbhi P. Chitnis, Calvin D. Pham, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21438-21469
Closed Access
Florian Wittlinger, Surbhi P. Chitnis, Calvin D. Pham, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21438-21469
Closed Access
Orthoallosteric EGFR‐TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation
Iqrar Ahmad, Harun Patel
Drug Development Research (2024) Vol. 86, Iss. 1
Closed Access
Iqrar Ahmad, Harun Patel
Drug Development Research (2024) Vol. 86, Iss. 1
Closed Access
